Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: A 5-year follow-up study of patients in the OPUS trial

Psychological Medicine

Volumn 44, Issue 1, 2014, Pages 117-126

  Clausen, L ^a   Hjorthoj, C R ^a   Thorup, A ^a   Jeppesen, P ^a   Petersen, L ^a   Bertelsen, M ^a   Nordentoft, M ^a  

^a Psychiatric Center Copenhagen   (Denmark)

Author keywords

Cannabis; cohort; follow up; medication; psychosis

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANNABIS SMOKING; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84889854747     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291713000433     Document Type: Article

References (44)

1. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 162, 441-449. (Pubitemid 40343909)
2. Anglin DM, Corcoran CM, Brown AS, Chen H, Lighty Q, Brook JS, Cohen PR (2012). Early cannabis use and schizotypal personality disorder symptoms from adolescence to middle adulthood. Schizophrenia Research 137, 45-49.
3. Archie S, Rush BR, Akhtar-Danesh N, Norman R, Malla A, Roy P, Zipursky RB (2007). Substance use and abuse in first-episode psychosis: prevalence before and after early intervention. Schizophrenia Bulletin 33, 1354-1363. (Pubitemid 350022769)
4. Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P (1995). A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Archives of General Psychiatry 52, 352-360.
5. Bertelsen M, Jeppesen P, Petersen L, Thorup A, Ohlenschlaeger J, le Quach P, Christensen TO, Krarup G, Jorgensen P, NordentoftM(2008). Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: The OPUS trial. Archives of General Psychiatry 65, 762-771. (Pubitemid 351957702)
6. Cannon-Spoor E, Potkin SG, Wyatt RJ (1982). Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin 8, 470-484.
7. Compton MT, Kelley ME, Ramsay CE, Pringle M, Goulding SM, Esterberg ML, Stewart T, Walker EF (2009). Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. American Journal of Psychiatry 166, 1251-1257.
8. D'Souza DC, bi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594-608. (Pubitemid 40409699)
9. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM (2009). High-potency cannabis and the risk of psychosis. British Journal of Psychiatry 195, 488-491.
10. Dragt S, Nieman DH, Schultze-Lutter F, van der Meer F, Becker H, de Haan L, Dingemans PM, Birchwood M, Patterson P, Salokangas RK, Heinimaa M, Heinz A, Juckel G, Graf von Reventlow H, French P, Stevens H, Ruhrmann S, Klosterkötter J, Linszen DH (2012). Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatrica Scandinavica 125, 45-53.
11. Dunn M, O'Driscoll C, Dayson D,WillsW, Leff J (1990). The TAPS Project. 4: An observational study of the social life of long-stay patients. British Journal of Psychiatry 157, 842-8, 852.
12. Faridi K, Joober R, Malla A (2012). Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. Schizophrenia Research 141, 78-82.
13. Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, Fätkenheuer B, Löffler W, van der Heiden W (1992). IRAOS: An instrument for the assessment of onset and early course of schizophrenia. Schizophrenia Research 6, 209-223.
14. Hjorthoj CR, Fohlmann A, Larsen AM, Arendt M, Nordentoft M (2012a). Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial. Addiction 107, 1123-1131.
15. Hjorthoj CR, Hjorthoj AR, Nordentoft M (2012b). Validity of Timeline Follow-Back for self-reported use of cannabis and other illicit substances-systematic review and meta-analysis. Addictive Behavior 37, 225-233.
16. Jeppesen P, Petersen L, Thorup A, Abel MB, Ohlenschlaeger J, Christensen TO, Krarup G, Jorgensen P, Nordentoft M (2008). The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychological Medicine 38, 1157-1166. (Pubitemid 351950154)
17. Kamali M, Kelly BD, Clarke M, Browne S, Gervin M, Kinsella A, Lane A, Larkin C, O'Callaghan E (2006). A prospective evaluation of adherence to medication in first episode schizophrenia. European Psychiatry 21, 29-33. (Pubitemid 43243050)
18. Large M, Sharma S, Compton MT, Slade T, Nielssen O (2011). Cannabis use and earlier onset of psychosis: A systematic meta-analysis. Archives of General Psychiatry 68, 555-561.
19. Larsen TK, Friis S, Haahr U, Johannessen JO, Melle I, Opjordsmoen S, Rund BR, Simonsen E, Vaglum PV, McGlashan TH (2004). Premorbid adjustment in first-episode non-affective psychosis: distinct patterns of pre-onset course. British Journal of Psychiatry 185, 108-115. (Pubitemid 39061453)
20. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Davey SG (2004). Psychological and social sequelae of cannabis and other illicit drug use by young people: A systematic review of longitudinal, general population studies. Lancet 363, 1579-1588. (Pubitemid 38625660)
21. McGrath J, Welham J, Scott J, Varghese D, Degenhardt L, Hayatbakhsh MR, Alati R, Williams GM, Bor W, Najman JM (2010). Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Archives of General Psychiatry 67, 440-447.
22. Miller R, Ream G, McCormack J, Gunduz-Bruce H, Sevy S, Robinson D (2009). A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophrenia Research 113, 138-144.
23. Moore THM, Zammit S, Lingfjord.Hughes A, Barnes TRE, Jones PB, Lewis G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370, 319-328. (Pubitemid 47094993)
24. Mors O, Perto GP, Mortensen PB (2011). The Danish psychiatric central research register. Scandinavian Journal of Public Health 39, 54-57.
25. Nelson HE (1982). National Adult Reading Test (NART). NFER-Nelson: Windsor.
26. Nordentoft M, Ohlenschlaeger J, Thorup A, Petersen L, Jeppesen P, Bertelsen M (2010). Deinstitutionalization revisited: A 5-year follow-up of a randomized clinical trial of hospital-based rehabilitation versus specialized assertive intervention (OPUS) versus standard treatment for patients with first-episode schizophrenia spectrum disorders. Psychological Medicine 40, 1619-1626.
27. Nordentoft M, Pedersen MG, Pedersen CB, Blinkenberg S, Mortensen PB (2012). The new asylums in the community: severely ill psychiatric patients living in psychiatric supported housing facilities. A Danish register-based study of prognostic factors, use of psychiatric services, and mortality. Social Psychiatry and Psychiatric Epidemiology 47, 1251-1261.
28. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB (2006). The Danish Civil Registration System. A cohort of eight million persons. Danish Medical Bulletin 53, 441-449. (Pubitemid 44816920)
29. Pedersen G, Hagtvet KA, Karterud S (2007). Generalizability studies of the Global Assessment of Functioning-Split version. Comprehensive Psychiatry 48, 88-94. (Pubitemid 44826972)
30. Petersen L, Jeppesen P, Thorup A, Abel MB, Ohlenschlaeger J, Christensen TO, Krarup G, Jorgensen P, Nordentoft M (2005). A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. British Medical Journal 331, 602.
31. Petersen L, Jeppesen P, Thorup A, Ohlenschlaeger J, Krarup G, Ostergard T, Jorgensen P, Nordentoft M (2007). Substance abuse and first-episode schizophrenia-spectrum disorders. The Danish OPUS trial. Early Intervention in Psychiatry 1, 88-96.
32. Quach PL, Mors O, Christensen TO, Krarup G, Jorgensen P, Bertelsen M, Jeppesen P, Petersen L, Thorup A, Nordentoft M (2009). Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder. Early Intervention in Psychiatry 3, 66-74.
33. Rubino T, Zamberletti E, Parolaro D (2012). Adolescent exposure to cannabis as a risk factor for psychiatric disorders. Journal of Psychopharmacology 26, 177-188.
34. Russell AJ, Munro J, Jones PB, Hayward P, Hemsley DR, Murray RM (2000). The National Adult Reading Test as a measure of premorbid IQ in schizophrenia. British Journal of Clinical Psychology 39, 297-305.
35. Schimmelmann BG, Conus P, Cotton S, Kupferschmid S, McGorry PD, Lambert M (2012). Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. European Psychiatry 27, 463-469.
36. Schimmelmann BG, Conus P, Cotton SM, Kupferschmid S, Karow A, Schultze-Lutter F, McGorry PD, Lambert M (2011). Cannabis use disorder and age at onset of psychosis-a study in first-episode patients. Schizophrenia Research 129, 52-56.
37. Sundhedsstyrelsen (2012). Narkosituationen i Danmark 2012 (ed. Sundhedsstyrelsen), pp. 1-117.
38. Sundhedsstyrelsen (Danish National Board of Health): Copenhagen. Thorup A, Petersen L, Jeppesen P, Ohlenschlaeger J, Christensen T, Krarup G, Jorgensen P, Nordentoft M (2005). Integrated treatment ameliorates negative symptoms in first episode psychosis-results from the Danish OPUS trial. Schizophrenia Research 79, 95-105. (Pubitemid 41362597)
39. van Dijk D, Koeter MW, Hijman R, Kahn RS, van den Brink W (2012). Effect of cannabis use on the course of schizophrenia in male patients: A prospective cohort study. Schizophrenia Research 137, 50-57.
40. WHO (1992). Life Chart Rating Form. Introduction to the Life Chart Schedule. World Health Organization: Geneva.
41. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N (1990). SCAN: Schedule for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry 47, 589-593. (Pubitemid 20189971)
42. Zamberletti E, Prini P, Speziali S, Gabaglio M, Solinas M, Parolaro D, Rubino T (2012). Gender-dependent behavioral and biochemical effects of adolescent delta-9-tetrahydrocannabinol in adult maternally deprived rats. Neuroscience 204, 245-257.
43. Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2008). Effects of cannabis use on outcomes of psychotic disorders: systematic review. British Journal of Psychiatry 193, 357-363.
44. Zammit S, Owen MJ, Evans J, Heron J, Lewis G (2011). Cannabis, COMT and psychotic experiences. British Journal of Psychiatry 199, 380-385.